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Abstract
Gedunin, a family of natural products from the Indian neem tree, possess a variety of biological activities. Here we report the
discovery of deoxygedunin, which activates the mouse TrkB receptor and its downstream signaling cascades. Deoxygedunin is
orally available and activates TrkB in mouse brain in a BDNF-independent way. Strikingly, it prevents the degeneration of
vestibular ganglion in BDNF 2/2 pups. Moreover, deoxygedunin robustly protects rat neurons from cell death in a TrkB-
dependent manner. Further, administration of deoxygedunin into mice displays potent neuroprotective, anti-depressant and
learning enhancement effects, all of which are mediated by the TrkB receptor. Hence, deoxygedunin imitates BDNF’s biological
activities through activating TrkB, providing a powerful therapeutic tool for treatment of various neurological diseases.
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Introduction
Neurotrophins (NT), a family of secreted proteins, are growth
factors that regulate the development and maintenance of the
peripheral and the central nervous systems [1]. Brain-derived
neurotrophic factor (BDNF) is a member of the neurotrophin
family, which includes nerve growth factor (NGF), NT-3 and NT-
4/5 [2]. Neurotrophins exert their biological functions on neurons
through two transmembrane receptors: the p75 neurotrophin
receptor (p75NTR) and the Trk receptor tyrosine kinases (NGF
binds to TrkA, BDNF and NT-4/5 bind to TrkB, and NT-3
preferentially binds to TrkC) [3,4]. Structurally, the extracellular
domain of Trk receptors consists of a cysteine-rich cluster (CC1),
followed by three leucine-rich repeats, another CC2 and two
immunoglobulin (Ig)-like domains, which are involved in ligand
binding. The cytoplasmic domain consists of a tyrosine kinase
domain surrounded by several tyrosines. BDNF binding to TrkB
triggers its dimerization through conformational changes and
autophosphorylation of tyrosine residues in its intracellular
domain, resulting in activation of the three major signaling
pathways involving mitogen-activated protein kinase (MAPK),
phosphatidylinositol 3-kinase (PI3K) and phospholipase C-c (PLC-
c). BDNF protects hippocampal neurons from glutamate toxicity
and rescues cerebellar neurons from programmed cell death [5,6].
BDNF reduces ischemic injury [7,8] and has been shown to
improve functional recovery and postinjury regeneration [9].
Moreover, BDNF is of particular therapeutic interest because of its
neurotrophic actions on neuronal populations involved in several
neurodegenerative diseases, including peripheral sensory neurop-
athies [10]; amyotrophic lateral sclerosis (ALS) [11]; Parkinson’s
disease (PD) and Alzheimer’s disease (AD) [12]. The preclinical
evidence strongly supports the idea that BDNF might be useful as
a therapeutic agent for a variety of neurological disorders.
However, the clinical trials with recombinant BDNF are
disappointing [13,14]. Presumably, this is due to the poor
pharmacokinetics of BDNF. So far, a few categories of TrkB
agonists have been reported, including monoclonal antibodies [15]
and peptide mimetics [16,17]. However, none of these agents have
been successfully developed to fully mimic BDNF and to act as
potent and selective in vivo agonists of TrkB.
In order to identify small molecules that mimic the neurotrophic
activities of BDNF, we developed a cell-based apoptotic assay
using a cell permeable fluorescent dye MR(DERD)2, which turns
red upon caspase-3 cleavage in apoptotic cells. Employing this
assay, we have successfully identified TrkA agonist gambogic
amide [18]. We then utilized a murine cell line T48, which was
derived from basal forebrain SN56 cells that contain undetectable
TrkB. T48 cells are TrkB stably transfected SN56 cells. Using this
caspase-activated fluorescent dye as a visual assay, we have now
screened thousands of compounds. Numerous compounds selec-
tively protected TrkB expressing T48, but not parental SN56 cells
lacking TrkB from Staurosporine-initiated apoptosis. This indi-
cates that these compounds might act either directly through TrkB
receptor or its downstream signaling effectors. The first round of
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11528Figure 1. Deoxygedunin protects neurons from apoptosis and it activates TrkB by autophosphorylation. (A) Chemical structures of
deoxygedunin and two other derivatives. (B) Gedunin derivatives suppress glutamate-provoked neuronal cell death. Hippocampal neurons were
pretreated with 0.5 mM gedunins for 30 min, followed by 50 mM glutamate treatment for 16 h. Quantitative analysis of neuronal apoptosis was
conducted. (C) Deoxygedunin inhibits OGD-triggered neuronal apoptosis in a dose-dependent manner.
doi:10.1371/journal.pone.0011528.g001
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neurons for TrkB activation and neuronal survival, which was
followed by ligand binding and dimerization assays for further
characterization. Recently, we have reported that 7,8-dihydroxy-
flavone (7,8-DHF) acts as a potent TrkB agonist [19].
As described in this manuscript, this screen identified a number of
gedunin derivatives. Gedunin, a tetranortriterpenoid isolated from
the Indian neem tree (Azadirachta indica), has demonstrated the
ability to exhibit antimalarial, insecticidal, and most recently
anticancer activity [20,21,22]. The antitumor activity of gedunin
was explored through the use of the connectivity map [23]. Lamb et
al. found, via high connectivity scores with GDA, 17-AAG, and 17-
DMAG, that gedunin exhibited its antiproliferative activity through
Hsp90 modulation. Gedunin was recently shown to manifest
anticancer activity via inhibition of the 90 kDa heat shock protein
(Hsp90) folding machinery and to induce the degradation of Hsp90-
dependent client proteins similar to other Hsp90 inhibitors. The
mechanism of action by which gedunin induces client protein
degradation remains undetermined, however, prior studies have
demonstrated that it does not bind competitively versus ATP. In this
report, we show that deoxygedunin also functions as a TrkB agonist,
which binds to the extracellular domain (ECD) of TrkB and
stimulates its dimerization and autophosphorylation. Moreover,
deoxygedunin selectively activates TrkB but not TrkA or TrkC in
BDNF independent fashion, and prevents neuronal apoptosis in a
TrkB dependent manner. Strikingly, administration of deoxygedunin
prevents vestibular ganglion loss in BDNF 2/2 pups. Further,
deoxygedunin displays robust neuroprotection and antidepressant
activities and enhances acquisition of conditioned fear. Thus,
deoxygedunin is a TrkB agonist and exerts its neuroprotection
through activating TrkB.
Results
Identification of gedunin derivatives as survival
enhancers
To search for small molecular TrkB agonists, we developed a cell-
based assay using T48 cells, which are TrkB stable transfected SN56
cells, based on the anti-apoptotic action of TrkB signalings. Among
66 positive hits, four are gedunin derivatives. The library also
contains numerous gedunin derivatives, which were inactive. The
chemical structures of the representative gedunin compounds are
depicted in Figure S1. To compare the apoptosis inhibitory activity,
we preincubated these compounds (0.5 mM) with hippocampal
neurons for 30 min, followed by 50 mM glutamate for 16 h. Among
the 12 gedunin derivatives, deoxygedunin displayed the most robust
protective effect, followed by alpha-dihydrogedunol (epoxy ring
down) and dihydrodeoxygedunin. However, other gedunins barely
suppressed apoptosis (Figure 1A & B). The neurons with both cleaved
caspase (MR(DEVD)2 red cells) and condensed nuclei (DAPI
staining) were counted as apoptotic cells. OGD (Oxygen-Glucose
Deprivation) is an in vitro model for ischemia stroke. BDNF reduces
ischemic injury [7,8]. To explore whether deoxygedunin exerts any
neuroprotective action against OGD, we pretreated hippocampal
neurons with 0.5 mM of gedunin derivatives for 30 min, followed by
3 h OGD stimulation (the culture medium was replaced by glucose-
free medium, and cells were transferred to a humidified incubation
chamber flushed by a gas mixture of 95% N2 and 5% CO2 at 37uC).
Deoxygedunin, alpha-dihydrogedunol (epoxy ring down) and
dihydrodeoxygedunin exhibited potent protective effects on hippo-
campal neurons under OGD. Titration assay reveals that deoxyge-
dunin protected neurons in a dose-dependent manner (Figure 1C).
Deoxygedunin activates TrkB and protects neurons from
apoptosis
To examine whether deoxygedunin triggers TrkB signaling
cascade, we conducted immunofluorescent staining and immuno-
blotting assays. The positive gedunin derivatives elicited TrkB
activation in rat hippocampal neurons (Figure 2A). Among a few
gedunin positive hits, deoxygedunin elicited the strongest stimulatory
effect. Hence, we selected it and focused on this compound.
Deoxygedunin activated TrkB in primary neuronal cultures in a
dose-dependent manner (Figure 2B). In hippocampal neurons,
deoxygedunin prominently provoked both Erk1/2 and Akt activation
with a time course (Figure 2C, left panels). It stimulated both Erk1/2
and Akt activation in a dose-dependent manner. The minimal
required drug concentration was about 100-250 nM (Figure 2C,
right panels). Hence, the activation patterns of TrkB receptor and its
downstream effectors including Akt and Erk1/2 by deoxygedunin
were tightly correlated. K252a is a Trk receptors inhibitor.
Pretreatment of K252a substantially blocked deoxygedunin-triggered
TrkB activation in cortical neurons (Figure 2D), indicating that
deoxygedunin can provoke TrkB autophosphorylation. Deoxygedu-
nin-provoked downstream Akt signalings were also reduced by
K252a. To assess whether deoxygedunin can provoke TrkB
activation in the brain, we injected mice (i.p.) with a dose of 5 mg/
kg for various time points. TrkB was selectively phosphorylated in the
brain 2 hafter injection, andpeakedat 4–8 h, so was the downstream
effectorsAkt and Erk1/2 activation (Figure 2E,leftpanels),suggesting
that deoxygedunin can penetrate the brain-blood barrier and
stimulate TrkB activation. Deoxygedunin was also orally bioactive
in provoking TrkB activation (Figure S2A). RT-PCR analysis
revealed no change of TrkA or TrkB in mouse brain upon
deoxygedunin treatment (Figure S2B), indicating that deoxygedunin
stimulates TrkB activation independent of Trk receptor transcrip-
tional alteration. Mouse monoclonal P-TrkB 817 antibody recog-
nized both human and mouse TrkB phosphorylation in addition to
rat TrkB (Figure S2C). Hence, deoxygedunin can strongly trigger
TrkB activation in vitro and in vivo.
Deoxygedunin binds TrkB ECD and provokes its
dimerization
To determine whether deoxygedunin directly binds TrkB, we
conducted a ligand binding assay with [
3H]deoxygedunin. Filter
assay demonstrated that increasing concentrations of [
3H]deox-
Figure2.DeoxygeduninactivatesTrkBandprotectsneuronsfromapoptosis.(A) Deoxygedunin activates TrkB in primary hippocampal neurons.
Hippocampalneuronswere treatedwith 500 nMgedunin derivatives for30 min and neurons werefixed andimmunostained withrabbit polyclonal anti-p-
TrkB (816) (1:100) and anti-MAP2. The nuclei were stained with DAPI. BDNF and a few gedunin derivatives selectively triggered TrkB phosphorylation in
neurons. (B) Deoxygedunin triggers TrkB activation in primary neurons. Rat cortical neurons were treated with various concentrations of deoxygedunin for
30 min. Neuronal lysates were subjected to immunoblotting analysis by mouse monoclonal anti-p-TrkB (817)(1:20,000). Equal amount of TrkB was loaded
(anti-TrkB from Biovision, 1:1,000) (lower panel). (C) Deoxygedunin provokes Akt and Erk1/2 activation in primary neurons in a dose and time-dependent
manner. Mouse monoclonal anti-TrkB 817 was used at 1:20,000 dilution. (D) K252a blocks deoxygedunin’s agonistic effect on TrkB. Cortical neurons were
pretreated with K252a (100 nM) for 30 min, followed by BDNF (100 ng/ml) or deoxygedunin (500 nM) for 30 min. Cell lysates were analyzed by
immunoblotting. (E) Deoxygedunin activates TrkB in mouse brain. Deoxygedunin (5 mg/kg) was intraperitoneally injected into mice and mouse brains
were dislocated at different time points. Brain lysates were analyzed by immunoblotting.
doi:10.1371/journal.pone.0011528.g002
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that TrkB ECD but not ICD selectively binds deoxygedunin. In
contrast, it did not bind to TrkA at all, indicating it specifically
associates with the extracellular domain of TrkB receptor
(Figure 3A). Scatchard plot analysis revealed that the ratio of
ligand to the receptor is 1:1 with binding constant Kd =1.4 mM
(Figure 3B). To test whether deoxygedunin triggers TrkB
dimerization, we cotransfected GST-TrkB with HA-TrkB plasmid
into HEK293 cells, and treated the cells with 0.5 mM of various
gedunin derivatives for 30 min. GST pull-down assay revealed
that deoxygedunin robustly provoked TrkB dimerization with an
effect even stronger than BDNF. Moreover, alpha-dihydrogedunol
Figure 3. Deoxygedunin binds TrkB ECD and elicits its dimerization. (A)[
3H]deoxygedunin binds the ECD but not ICD of TrkB receptor. In
vitro binding assay with purified TrkB ECD or ICD (10 mg) and [
3H]deoxygedunin (upper panel). In vitro binding assay with purified fragments of TrkB
ECD (10 mg) and [
3H]deoxygedunin. (B) Determination of binding constant. Binding curve (upper panel). Scatchard plot analysis revealed that
deoxygedunin binds TrkB with binding constant of 1.4 mM (lower panel). (C) Deoxygedunin provokes TrkB dimerization. mGST-TrkB and HA-TrkB
were cotransfected into HEK293 cells, treated with 0.5 mM various gedunins for 30 min. GST-TrkB was pulled down by glutathione beads, the
coprecipitated proteins were analyzed with anti-HA HRP antibody. (D) Deoxygedunin induces TrkB autophosphorylation. HEK 293 cells were
transfected with various Trk receptors, followed by deoxygedunin treatment for 30 min. Cell lysates were analyzed by immunoblotting assay.
doi:10.1371/journal.pone.0011528.g003
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(Figure 3C, top panel), fitting with its stimulatory activity on TrkB
(Figure 2). The coprecipitated HA-TrkB was also prominently
tyrosine phosphorylated (3
rd panel). Hence, deoxygedunin directly
binds TrkB ECD and triggers its association. Deoxygedunin also
elicited tyrosine phosphorylation in TrkB but not in TrkA or TrkC
receptor in transfected HEK293 cells. TrkB-KD displayed
negligible phosphorylation compared to wild-type TrkB
(Figure 3D), indicating that TrkB phosphorylation by deoxygedu-
nin is through the receptor autophosphorylation but not by any
other tyrosine kinases. Therefore, deoxygedunin binds to the ECD
of TrkB and promotes its association and activation.
Deoxygedunin protects neurons from apoptosis in a
TrkB-dependent manner
To determine if deoxygedunin’s neuronal protective effect is
mediated through TrkB receptor, we prepared cortical neurons
from pups of TrkB +/2 mice, which were mated to the same
genotype. Deoxygedunin specifically activated TrkB but not TrkA
receptor in wild-type but not TrkB 2/2 neurons. 7,8-dihydroxy-
flavone (7,8-DHF), another positive compound from the screening,
also selectively activated TrkB but not TrkA. The tricyclic
antidepressant drugs amitriptyline but not imipramine activated
both TrkA and TrkB (Figure 4A, top and 3
rd panels). Glutamate-
provoked caspase-3 activation was substantially blocked by 7,8-
DHF and deoxygedunin in wild-type but not TrkB 2/2 neurons.
However, the control compound imipramine failed to blocked
caspase-3 activation by glutamate. In contrast, amitriptyline
weakly suppressed caspase-3 activation in both wild-type and
TrkB 2/2 neurons (Figure 4A, bottom panels). Thus, deoxyge-
dunin selectively suppressed apoptosis triggered by glutamate in a
TrkB-dependent manner. Moreover, deoxygedunin strongly
provoked TrkB but not TrkA activation in both wild-type and
TrkC knockout neurons (Figure 4B, top panel). Noticeably, the
spontaneous caspase-3 activation in TrkC 2/2 neurons was
suppressed by deoxygedunin. Further, glutamate-triggered cas-
pase-3 activation was significantly diminished by deoxygedunin
(Figure 4B, bottom panel), demonstrating that it represses
neuronal apoptosis is TrkB- but not TrkC-dependent.
To investigate whether the neuroprotective effects of deoxyge-
dunin is reliant on TrkB activation in vivo, we employed TrkB
F616A knock-in mice, where it has been shown that TrkB F616A
can be selectively blocked by 1NMPP1, a TrkB F616A inhibitor,
resulting in an effective TrkB-null phenotypes [24]. To assess
whether deoxygedunin can mimic BDNF, we prepared cortical
neurons from TrkB F616A knock-in mice. Fitting with the
previous report, BDNF-provoked TrkBF616A phosphorylation
was selectively blocked by 1NMPP1 but not K252a. We made the
same finding with deoxygedunin (Figure 4C, top panel). 1NMPP1,
but not K252a, blocked BDNF-triggered Akt and Erk1/2
activation. Similarly, 1NMPP1 completely diminished Akt and
Erk1/2 activation by deoxygedunin (Figure 4C, 3
rd and 5
th
panels). Since 1NMPP1 selectively inhibits TrkB F616A activation
by deoxygedunin, we hypothesized that blockade of TrkB F616A
signaling by 1NMPP1 in mice would make the neurons vulnerable
to KA-provoked neuronal cell death. We pretreated the mice with
1NMPP1, followed by deoxygedunin and KA treatment. In 5
days, we monitored neuronal cell death in hippocampal region by
immunoblottings. As predicted, 1NMPP1, deoxygedunin alone or
1NMPP1 + deoxygedunin combined treatment had no effect on
apoptosis in TrkB F616A mice. KA caused marked caspase-3
activation, and pretreatment of 1NMPP1 mildly elevated KA-
provoked apoptosis in TrkB F616A, supporting that TrkB
signaling is critical for neuronal survival. Deoxygedunin evidently
suppressed KA-provoked apoptosis, whereas 1NMPP1 pretreat-
ment greatly diminished deoxygedunin’s protective effect in
F616A mice. TrkB activation status inversely correlated with
TrkB activation by deoxygedunin (Figure 4D, top and middle
panels). Hence, these data support that deoxygedunin selectively
activates TrkB receptor and enhances neuronal survival in mice in
TrkB dependent manner.
Deoxygedunin activates TrkB in BDNF independent
manner and prevents vestibular ganglion loss
To examine whether deoxygedunin activating TrkB involves
endogenous BDNF, we employed BDNF conditional knockout mice
with BDNF gene deletion limited to cortex, thus allowing normal
development. We intraperitoneally injected deoxygedunin (5 mg/kg)
into BDNF cortex conditional knockout mice and sacrificed the mice
at 4 h. Immunoblotting analysis with the cortical lysates demonstrated
robust TrkB activation in both wild-type and BDNF 2/2 mice
(Figure 5A), underscoring that deoxygedunin activates TrkB inde-
pendent of BDNF. Mutant mice lacking BDNF have severe
deficiencies in coordination and balance, associated with excessive
degeneration in several sensory ganglia including the vestibular
ganglion [25]. To determine whether deoxygedunin rescues the loss of
vestibular ganglions in BDNF 2/2 pups, we bred the conventional
BDNF +/2 mice with the same genotype mice, and administered
deoxygedunin (5 mg/kg, i.p.) to the pregnant mice at day E7.5 until
birth. The neonatal pups continued receiving the same dose of
deoxygedunin, but BDNF 2/2 pups continued dying at P1 or P2.
Staining of inner ear sections showed that vestibular ganglia were
completely lost in most of control vehicle-treated BDNF 2/2 pups.
In contrast, many of deoxygedunin-treated BDNF mutant mice
displayed intact vestibular ganglia, similar to the wild-type pups
(Figure 5B, left panels). Quantitative analysis demonstrated that 9.1%
of vestibular ganglia were detected in vehicle-treated BDNF 2/2
pups,whereasdeoxygedunintreatmentincreasedto42.2%(Figure5B,
rightpanel).Wemadeasimilarobservationwith7,8-DHF(Figure5C).
Therefore, deoxygedunin mimics BDNF and significantly protects
vestibular ganglia from degeneration in BDNF -/- pups.
TrkB agonists have potent antidepressant effect
BDNF plays an essential role in mediating antidepressants’
therapeutic effects [26,27,28,29]. Infusion of exogenous BDNF
into hippocampus or brain stem has anti-depressant-like behav-
ioral effects [30,31]. A forced swim test is broadly used for
screening of potential antidepressant drugs and is widely used to
measure antidepressant activity [32,33]. To investigate whether
these TrkB agonists mimic BDNF in suppressing depression-like
symptoms, we conducted a forced swim test after subchronic
treatment of the mice for 5 days with various drugs. When mice
were treated with imipramine (20 mg/kg), a tricyclic antidepres-
sant drug, the swimming immobility was significantly decreased.
Interestingly, both 7,8-DHF and deoxygedunin (5 mg/kg) reduced
the immobility with deoxygedunin revealing a more potent effect
(Figure 6A). To assess whether the behavior responses by 7,8-DHF
and deoxygedunin are mediated by TrkB receptor, we utilized
TrkB F616A knockin mice. The transgenic mice were subjected
saline or 1NMPP1 treatment, respectively. No significant differ-
ence was observed in the immobility time between saline and
1NMPP1-treated mice. In saline group, 7,8-DHF and deoxyge-
dunin substantially reduced the immobility time; in contrast, 7,8-
DHF and deoxygedunin had no significant effect in mice, when
TrkB was blocked by 1NMPP1 (Figure 6B), suggesting that
inhibition of the TrkB signaling cascade inhibits the antidepressant
effect of these drugs. Thus, these data demonstrate that the TrkB
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mice through activating the TrkB receptor.
Deoxygedunin enhances acquisition of conditioned fear,
a BDNF-dependent learning process
We next wished to examine whether this TrkB agonist would
enhance learning in a whole animal model of learning and
memory, in which BDNF-dependent TrkB activation is required.
Activation of TrkB by BDNF has been repeatedly shown to be
associated with, and required for, the acquisition of classical
conditioned fear in rodent models [34,35,36,37,38,39]. Following
habituation to the testing context, 28 adult wild-type, C57BL/6J
mice were given systemic injections of deoxygedunin (N=14,
5 mg/kg, i.p.) or vehicle (N=14) 1 hr prior to tone-shock fear
conditioning in a novel context (Figure 7A). There was no
difference between treatment groups in shock reactivity during
Figure 5. Deoxygedunin activates TrkB in a BDNF-independent manner and prevents vestibular ganglion loss. (A) Deoxygedunin
triggers TrkB activation in BDNF conditional knockout cortex. 2–3 months old BDNF cortex conditional knockout mice were intraperitoneally injected
with 5 mg/kg deoxygedunin. In 4 h, the mice were sacrificed and brain lysates were analyzed by immunoblotting. (B&C ) Deoxygedunin and 7,8-
DHF prevent vestibular ganglion loss in BDNF 2/2 pups. BDNF +/2 mice were mated with the same genotypes of mice. At E7.5 days, the pregnant
mothers were administrated with 5 mg/kg deoxygedunin or 7,8-DHF until birth. The neonatal pups continued on drug treatment for 1 or 2 days till
death. The inner ear sections were stained with toluidine blue.
doi:10.1371/journal.pone.0011528.g005
Figure 4. Deoxygedunin protects neurons from apoptosis in a TrkB-dependent manner. (A) Deoxygedunin prevents glutamate-triggered
neuronal apoptosis in wild-type but not TrkB null neurons. Cortical neurons were prepared from the P0 pups (TrkB +/2 x TrkB +/2). The neurons
were pretreated with a variety of compounds as indicated for 30 min, followed by 50 mM glutamate for 16 h. The cell lysates were analyzed by
immunoblotting with anti-p-TrkB, anti-p-TrkA and anti-active caspase-3 etc. (B) Deoxygedunin diminishes caspase-3 activation regardless of TrkC
genotype. (C) Deoxygedunin selectively activates TrkB F616A, which can be blocked by 1NMPP1. Primary cortical neurons were prepared from TrkB
F616A knockin mice. The primary cultures were pretreated for 30 min with either K252a Trk tyrosine kinase inhibitor (100 nM) or 1NMPP1 inhibitor
(100 nM), followed by 0.5 mM Deoxygedunin for 30 min. Immunoblotting with various antibodies were performed. (D) Deoxygedunin suppresses KA-
induced neuronal cell death in TrkB F616A mutant mice, which can be blocked by 1NMPP1. TrkB F616A knockin mice were treated with following
reagents: saline, 1NMPP1, kainic acid, 1NMPP1 + kainic acid, deoxygedunin, 1NMPP1 + deoxygedunin, 1NMPP1 + deoxygedunin + kainic acid, as
described in experimental section. Immunoblotting was conducted with indicated antibodies.
doi:10.1371/journal.pone.0011528.g004
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effects on pain sensitivity that would affect fear acquisition or
later fear expression (p..1; Figure 7B). Mice were then tested,
with no additional drug treatment, for cue-conditioned fear in the
previously habituated context on the two days following fear
acquisition. The average level of tone-dependent conditioned
freezing was significantly different on both testing days (Figure 7C;
repeated measures ANOVA, F(1,26)=6.6, p=.016) suggesting
that mice that received deoxygedunin at the time of training had
enhanced acquisition or consolidation of the fear memory. To
further explore these effects, we examined individual animals’
freezing levels throughout the tone-fear testing sessions. We found
on both testing day 1 (Figure 7D) and day 2 (Figure 7E) that the
enhancement in freezing only corresponded with the periods of
tone cue presentation. The mice demonstrated similar levels of
locomotor exploratory activity prior to and in-between tone
exposure in this context, but the animals that received
deoxygedunin during the previous tone-shock fear conditioning
demonstrated significantly increased freezing during cued fear
presentations (Day 1, repeated measures ANOVA of first 4 CS
trials, F(1,26)=8.1, p,.01; Day 2, F(1,26)=7.5, p,.01). This
increase in fear learning led to a 2–3 fold increase in the level of
freezing during the first set of conditioned stimulus (CS) trials
examined each day. Together, these results suggest that although
deoxygedunin does not affect apparent level of pain or shock
reactivity during training, nor does it affect general locomotor
activity in the testing situation on subsequent days, the learning
event that occurred during training in the presence of systemic
deoxygedunin compared with vehicle was acquired or consoli-
dated in a more effective manner. Since cue-dependent fear
conditioning is known to require, and be exquisitely sensitive to,
BDNF activation of TrkB, these data are consistent with
deoxygedunin acting on the TrkB system in vivo to enhance
cue-dependent fear learning.
Discussion
In the present study, we have demonstrated that deoxygedunin
directly binds the ECD of TrkB and promotes its dimerization and
activation. Deoxygedunin provokes TrkB activation in primary
neurons and in mouse brain. It strongly protects neurons from
apoptosis in a TrkB- dependent manner. Further, it activates TrkB
in BDNF conditional knockout mice, indicating that BDNF is not
implicated in the stimulatory effect of deoxygedunin. When it is
injected in animals, deoxygedunin mimics BDNF and exerts
neuroprotective and antidepressant actions and enhances learning
processes. Moreover, administration of 7,8-dihydroxyflavone and
deoxygedunin into pregnant BDNF +/2 mothers substantially
rescues vestibular ganglia, which are significantly degenerated in
BDNF 2/2 pups.
To determine which chemical group or moiety is critical for the
neurotrophic activity of gedunin, we have conducted a structure-
activity relationship study. The results suggest that the epoxy ring
confirmation in the D ring is essential for gedunin’s agonistic
activity. It has to be in a down conformation for the agonist to be
effective. Nevertheless, the alpha-beta unsaturated ketone in ring
A is variable. Reduction of the unsaturated C=C bond did not
impair its stimulatory activity, suggesting that this site can tolerate
a potential chemical modification, which might be useful for
improving its water solubility and biological activity. When the
epoxy group is in down conformation, changing ketone into
alcohol did not cripple its agonistic effect either regardless of alpha
or beta conformation of the resulting hydroxy group. Nevertheless,
deoxygedunin displays the strongest agonistic effect, suggesting
that ketone might be more active than alcohol in ring A (Figure
S1). We have recently shown that 7,8-DHF and NAS (N-
acetylserotonin) potently activate TrkB receptor. Structurally,
these two compounds share the hydroxyphenol group. Our
structure-activity study in 7,8-DHF shows that the 7-position
hydroxyl group is critical for its agonist effect. This position
Figure 6. TrkB agonists are robust antidepressants. (A) Forced swim test. 2–3-month-old Male mice (n=8 mice/group) were treated with
imipramine (20 mg/kg), deoxygedunin (5 mg/kg), 7,8-DHF (5 mg/kg) and vehicle solvent saline by intraperitoneal injection for 5 days, and subjected
to a forced swim test (6 min, immobility recorded in the last 4 min). (B) Forced swim test with TrkB F616A knockin mice. Male TrkB knockin mice were
given the regular drinking water or 1NMPP1 containing drinking water one day before the drugs. Deoxygedunin/1NMPP1 group is significantly
different from the water group but not from control in 1NMPP1. Data are presented as mean 6 SEM of n=8–10 mice/group (**P,0.01 and
***P,0.001 against vehicle control group, One-way ANOVA, Dunnett’s test).
doi:10.1371/journal.pone.0011528.g006
Deoxygedunin Is a TrkB Agonist
PLoS ONE | www.plosone.org 9 July 2010 | Volume 5 | Issue 7 | e11528parallels the 5-position hydroxyl group on the indole ring in NAS.
Conceivably, these two compounds share the same binding pocket
on TrkB ECD. However, they are quite different from
deoxygedunin in structure. The latter belongs to terpenoid family
members. Deoxygedunin might bind to different motif on TrkB
ECD from that of 7,8-DHF and NAS.
Gedunin, a tetranortriterpenoid isolated from the Indian neem
tree (Azadirachta indica), and was recently shown to manifest
anticancer activity via inhibition of the 90 kDa heat shock protein
(Hsp90) folding machinery and to induce the degradation of
Hsp90-dependent client proteins similar to other Hsp90 inhibitors
[20,21,22,23,40]. Intraperitoneal injection of deoxygedunin
(5 mg/kg) into mice triggers TrkB activation in mouse brain after
2 h and peaked at 4–8 h, indicating that this compound or its
metabolites can pass brain blood barrier and has a fairly long
effective duration. To monitor its tissue distribution and kinetics of
degradation after i.p. injection, we collected different brain regions
and body organs 4 h after
3H-deoxygedunin administration.
3H-
labeled compounds were concentrated in olfactory bulb and
hippocampus in the brain. Clearly, the brain as a whole organ was
the major tissue in the body where
3H-labeled compound was
accumulated, followed by the lung (Figure S4). Obviously,
substantial amount of
3H-deoxygedunin and its metabolites
remained in the brain 4 h after drug administration, indicating
this compound might possess a favorable half-life in the body.
Further, it can activate TrkB in mouse brain via oral administra-
tion. Nevertheless, deoxygedunin and other derivatives have poor
water solubility. In order to alleviate this issue, we are now
synthesizing various novel derivatives directly from deoxygedunin
that possess better water solubility while maintaining its biological
efficacy. Our rationale for modifying the skeleton of deoxygedunin
will occur in two phases. In the first phase, we will modify the
furan ring in the hopes of increasing solubility. In the second
phase, we will modify the ABCD rings of the solubilized
deoxygedunin derivatives (from phase one) in order to improve
their biological activity.
Deoxygedunin binds to the ECD domain of TrkB (Figure 3).
Interestingly, deoxygedunin and alpha-dihydrogedunol (epoxy
Figure 7. Deoxygedunin enhances acquisition of conditioned fear, a BDNF-dependent learning process. (A) Outline of Deoxygedunin
(DG) fear conditioning experiment. Mice were handled and habituated to testing context on the first two days, followed by systemic DG (5 mg/kg,
i.p.) 1 hr prior to fear conditioning (5, 0.5mA shock-tone pairings), followed by testing in the absence of drug on days 4–5. (B) Shock reactivity during
fear conditioning, demonstrating that the acute effects of the drug did not affect pain or fear responsiveness. (C) Total freezing to the conditioned
cue was significantly greater on both the first and second testing day in the mice that received DG with fear conditioning. (D&E ), Freezing activity
during the habituation period and first 4 CS presentations on test day 1 (D)o r2( E). There was no difference in animal activity in the test chamber
prior to the onset of the conditioned cue, or between cue presentations. However there was significantly increased fear, as measured with
conditioned freezing, during conditioned stimuli (CS). Dark bars represent tone conditioned stimulus presentations; **, p,0.01, *, p,0.05 between
DG and vehicle groups.
doi:10.1371/journal.pone.0011528.g007
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fected HEK293 cells, leading to TrkB receptor association and
autophosphorylation. However, competition assay shows that
deoxygedunin is unable to compete off BDNF bound to TrkB
(data not shown). Presumably, it is due to its much weaker binding
affinity (1.4 mM) than BDNF (Kd ,10
210 M). Although the
detailed molecular mechanism of how a ligand provokes Trk
receptor activation remains unclear, a conformational change
hypothesis has been proposed. For instance, a mutation at P203A
can cause spontaneous dimerization and activation of TrkA [41],
suggesting that ligand-provoked receptor dimerization might be
through triggering conformational change. Conceivably, deox-
ygedunin binding to TrkB might elicit its conformational change,
leading to its dimerization. Remarkably, although dihydrodeox-
ygedunol, 3-alpha-acetoxy-dihydro-deoxygedunin and 3-deoxo-3-
beta-acetoxy-deoxydihydrogedunin failed to provoke HA-TrkB to
bind GST-TrkB, the precipitated GST-TrkB was strongly
phosphorylated by these chemicals. This partial agonistic effect
fits with their weak stimulatory activity on TrkB receptor
(Figure 1B, C and 2A, B). The maximal activation following
ligand binding requires initial autophosphorylation of tyrosine
residues 670, 674, and 675 on TrkB [42,43]. Previous studies
suggest the following model for Trk activation: in the ligand-
unbound state, the activation loop blocks access of substrates to the
active site of the kinase domain. Ligand binding permits
autophosphorylation of the activation-loop tyrosines. Once
phosphorylated, each of these forms specific charge-pair interac-
tions with nearby standing positive charges. Such interactions in
turn stabilize an ‘‘open’’ conformation in which the activation loop
no longer blocks access of substrates to the kinase. This stabilized
conformation now effectively phosphorylates inter- and intramo-
lecular target [42]. Conceivably, the robust GST-TrkB phosphor-
ylation might result from the intramolecular reaction in the
stabilized conformation by the 3 chemicals mentioned above.
We have shown that both 7,8-DHF and deoxygedunin bind to
the ECD of TrkB and provoke the receptor dimerization
autophosphorylation. They both display comparable agonistic
activity on TrkB receptor. Moreover, they both minic BDNF by
exhibiting robust neuroprotective effect in stroke, neuroexcito-
toxicity, and vestibular ganglia survival assays. In addition, these
two compounds also display strong activity in learning and
memory and depression in animal models. Forced swim test
revealed that deoxygedunin might possess more robust antide-
pressant effect than 7,8-DHF (Fig. 6).
Taken together, these two small molecules basically share the
same biological and therapeutic actions. Nonetheless, 7,8-DHF is
water soluble, but deoxygedunin is not. The latter has more
complicated structure scaffold than the former. The flavonoids are
easier for medicinal modification to improve their biological effect
than gedunin family members.
BDNF and TrkB receptor are targets for therapeutic interven-
tion in various neurological diseases including neuroexcitotoxicity,
stroke, depression, anxiety, neurodegeneration etc. Nevertheless,
BDNF is not useful as a therapeutic agent because of its poor
pharmacokinetic properties. To search for small molecules that
possess robust TrkB agonistic activity, here, we invented a cell-
based survival functional assay. Our high-throughput screen was
focused on the neuronal survival function provided by the TrkB
receptor. Only the compounds that selectively protect TrkB
expressing cells but not parental cells without TrkB from apoptosis
were subjected to next round functional analysis. Hence, the
positive hits from the first round screen either directly activate
TrkB as an agonist or facilitate the downstream survival
machinery mediated by TrkB receptor. The second round
screening in primary neurons and follow-up TrkB association
and autophosphorylation analyses eliminate compounds that did
not directly target TrkB receptor. Through the in vitro receptor/
ligand binding assay, in vivo TrkB activation and neuronal survival
experiments, we finally obtained a few potent and selective TrkB
agonists that virtually mimic BDNF’s biochemical and physiolog-
ical actions, and 7,8-DHF and deoxygedunin are the most
promising lead compounds. Employing a variety of animal
models, we have established that deoxygedunin exhibits potent
neuroprotective actions in kainic acid neuroexcitotoxicity and
stroke animal models (see also Supplemental Materials S1 and
Figure S3). Moreover, we found that vestibular ganglion loss in
BDNF 2/2 pups was significantly blocked by the drug treatment
(Figure 5). This finding demonstrates that TrkB agonists can
protect vestibular ganglia from degeneration in BDNF-lacking
mice. Further, we show that both 7,8-DHF and deoxygedunin
display prominent antidepressant action in forced swim test, which
is also TrkB dependent (Figure 6). BDNF/TrkB signaling is also
associated with and required for the acquisition of classical
conditioned fear in rodent models [34,35,36,37,38,39]. Once
again, we demonstrated that deoxygedunin enhances acquisition
of conditioned fear, which is a BDNF-dependent learning process
(Figure 7). Therefore, all of these animal models strongly support
the notion that deoxygedunin mimics BDNF in vitro and in vivo and
reveal remarkably therapeutic activities in various neurological
diseases.
In CNS, physiological activities regulate local BDNF synthesis
and secretion, providing neurotrophic support necessary for the
BDNF-responsive tissues in a timely, dynamic fashion. In some
regions, neurotrophins act by either a paracrine or an autocrine
mechanism, while other neurons could compete for the same
factor in the more classical long-range, target-derived paradigm
[44,45]. However, it is impossible for the small molecular TrkB
agonists to meet the needs of TrkB activation in tissues that require
temporal and spatial regulation by like BDNF or NT-4/5. The
finding that 7,8-DHF and deoxygedunin rescue the survival of
vestibular ganglia in BDNF 2/2 pups supports that these TrkB
agonists partially supplement the deficiency of BDNF in mice.
Undoubtedly, further chemical modification on these lead
compounds to improve their agonistic activities and binding
affinities might provide powerful tools for us to dissect the




F616A mice, TrkB +/2, TrkA +/2 and BDNF +/2
C57BL/6 mice were bred in a pathogen-free environment in
accordance with Emory Medical School guidelines. All animal
experiments were performed according to the care of experimental
animal guidelines from Emory University and were approved by
Emory Institutional Animal Care and Use Committee (Protocol
no. 060-2009).
Cells and reagents
Human embryonic kidney HEK293 cell lines were grown in
medium A (DMEM with 10% fetal bovine serum (FBS) and 100
units penicillin-streptomycin) at 37uC with 5% CO2 atmosphere in
a humidified incubator [19]. Mouse septal neuron x neuroblas-
toma hybrids SN56 cells were created by fusing N18TG2
neuroblastoma cells with murine (strain C57BL/6) neurons from
postnatal 21 days septa [19]. SN56 cells were maintained at 37uC
with 5% CO2 atmosphere in DMEM medium containing 1 mM
pyruvate and 10% FBS. T48 and T62 cells, stably transfected with
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containing 300 mg/ml G418 [19]. NGF and BDNF were from
Roche. Phospho-Akt-473 or 308, Akt antibodies were from Cell
Signaling. Anti-phospho-Erk1/2, anti-phospho-TrkA Y785 were
from R & D Systems. Anti-TrkA antibody was from Santa Cruz.
Anti-TrkB antibody was from Biovision. Anti-p-TrkB (816) was a
gift from Dr. Moses Chao. Anti-p-TrkB 817 antibody was from
Epitomics, and it was marked under each blot. The chemical
library containing 2000 biologically active compounds was from
The Spectrum Collection (MicroSource Discovery System, Inc.
Gaylordsville, CT 06755). TrkB
F616A mice have been described
previously [24]. [
3H]Acetic acid, sodium salt was purchased from
Perkin Elmer (specific activity: 75–150 mCi/mmol; concentration:
10 mCi/mL). Deoxygedunin was purchased from Gaia Chemi-
cals, Inc. All other chemicals were purchased from Sigma or Alfa
Aesar.
Cell-based Screen
TrkB stable transfected SN56 cells (T48 cells) were seeded in a
96-well plate at 10,000 cells/well in 100 ml complete medium.
Cells were incubated overnight, followed by 30 min pretreatment
with 10 mM compounds in DMSO (10 mM stock concentration
from The Spectrum Collection library). The cells were then
treated with 1 mM staurosporine for 9 h. One h before the
termination of the experiment, 10 mM MR(DEVD)2, a cell
permeable caspase-3-activated fluorescent dye was introduced.
Cells were fixed with 4% paraformaldehyde for 15 min. Cells were
washed with PBS and incubated with 1 mg/ml of Hoechst 33342
for 10 min. Cover slides were washed with PBS, mounted, and
examined using a fluorescence microscope.
Preparation of 32-[
3H]3deoxygedunin at Georgia Institute
of Technology
[
3H]Acetic acid, sodium salt (11 mmol, 0.17 mL, 0.17 mL of
ethanol solution) is syringed into a heavy-walled glass vial bearing
a magnetic stirrer. The ethanol is removed under vacuum and
replaced with 0.5 mL of THF at 0uC. Isobutylchloroformate
(3.0 mL, 23 mmol) was then added and the reaction mixture was
stirred for 1 h at 0uC. A solution of 7-deacetyldeoxygedunin
(5 mg, 11 mmol), prepared by acetyl deprotection of deoxygedunin
with K2CO3 in MeOH, in 0.5 mL THF was then added dropwise.
The reaction was stirrer for another 1 h. Solvent was removed
under vacuum and the product was purified by preparative thin
layer chromatography (SiO2; 1:1 EtOAc:hexanes) to give 3 mg
(58%) of 32-[
3H]3deoxygedunin. Note: Preparation of 32-
[
3H]3deoxygedunin occurred only after preparation of deoxyge-
dunin under identical reaction conditions in order to confirm
product formation.
TrkB dimerization Assay
HEK293 cells that were transfected with GST-TrkB and HA-
TrkA or TrkB were washed once in PBS, and lysed in 1 ml lysis
buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5%
Triton X-100, 1.5 mM Na3VO4, 50 mM NaF, 10 mM sodium
pyrophosphate, 10 mM sodium b-glycerophosphate, 1 mM phe-
nylmethylsulfonyl flouride (PMSF), 5 mg/ml aprotinin, 1 mg/ml
leupeptin, 1 mg/ml pepstatin A), and centrifuged for 10 min at
14,0006ga t4 uC. The supernatant was transferred to a fresh tube.
Transfected TrkB receptor was pulled down with glutathione
beads, and the coprecipitated proteins were resolved on SDS-
PAGE. The samples were transferred to a nitrocellular membrane,
and immunoblotting analysis was performed with a variety of
antibodies.
Primary rat cortical or hippocampal neuron culture
Primary rat cortical or hippocampal neurons were prepared as
follows. E17 rat pups were decapitated and cortex or hippocampus
was extirpated, cross chopped and suspended by pipetting for
separation in 5% fetal calf serum (FCS), 5% horse serum (HS)
DMEM gently. The cell suspension was then centrifuged at 2506
g for 5 min. This operation was repeated again. Cells were seeded
into polyethyleneimine-coated 10 dishes and 12-well plates
including coated-coverslips and incubated at 37uCi n5 %C O 2/
95% air. After 3 h, the culture medium was changed to
Neurobasal containing B-27 supplement (Invitrogen) and incubat-
ed for 4 days. For maintenance, a half medium is changed to fresh
Neurobasal/B27 every 4 days. After 2 weeks, the cultured neurons
are used in various experiments.
Binding constant determination
Purified TrkB ECD or ICD proteins (10 mg/each) were
incubated with different [
3H-deoxygedunin] in 1 ml binding
buffer (0.05 M Na/K phosphate buffer (pH 7.1), 200 mM NaCl)
(1 nM [
3H]deoxygedunin ,82300 cpm) at 4uC for 10 min. After
the incubation, the reaction mixture was loaded on filter paper.
The mixture was washed with 365 ml Tris buffer (100 mM Tris,
pH 7.1). The dried filter paper was put into a small vial and
subjected to liquid scintillation counter analysis. The value of the
dissociate constant and the number of sites were obtained from
Scatchard plots by using the equation r/[L]free = n/Kd - r/Kd,
where r is the ratio of the concentration of bound ligand to the
total protein concentration and n is the number of binding sites.
Deoxygedunin suppresses KA-induced neuronal cell
death
Male C57BL/6 mice aged of 60 days were injected intraper-
itoneally (i.p.) with a single dose of either 20% DMSO in saline or
KA (20 mg/kg) (Sigma, MO) or deoxygedunin (5 mg/kg) followed
by KA. Animals were continually monitored for 2 h for the onset
of seizure activity. For most of the mice, the seizure stopped a few
hours after KA administration. At 5 days following treatment,
animals were anesthetized and perfused with 4% paraformalde-
hyde in 0.1 M phosphate buffered saline. Brains were removed,
post-fixed overnight and processed for paraffin embedding. Serial
sections were cut at 5 m and mounted on slides (Superfrost-plus,
Fisher). The slides were processed for TUNEL staining in order to
assess the degree of DNA fragmentation in hippocampal regions.
For KA treatment on TrkB F616A knockin mice, the mice were
pretreated with saline or 1NMPP1 (16.6 ng/kg, i.p.) on day before
the drug treatment. Deoxygedunin (5 mg/kg) was intraperitone-
ally administrated on mice. In 4 h, KA (20 mg/kg) was injected
into the mice. Then the mice were supplied with drinking water
containing 1NMPP1 (50 mM) for another 4 days. In day 5, the
mice were sacrificed and the hippocampal regions were analyzed
by immunoblotting.
Cortex- Specific BDNF Deletion
The Cortex-Specific Cre mouse line was previously described as
‘‘transgenic line C’’ [46]. Briefly, coding sequence for Cre-
recombinase (Cre-IRES-DsRed2) was placed downstream of a
3 kb cholecystokinin (CCK) promoter, linearized, purified, and
microinjected into the pronuclei of one-cell C57/BL6 embryos,
which were then implanted into pseudo-pregnant C57/BL6
females. The purification and injections were performed at the
Emory University Transgenic Facility. Following verification of
gene expression in the different transgenic lines [47], we crossed
the cortex-specific ‘‘line C’’ to a floxed-stop lacZ reporter mouse
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specific Cre gene expression and BDNF deletion were confirmed
with in situ hybridization, x-gal staining for b-galactosidase
expression, and western blot for BDNF protein levels.
Immunofluorescent staining on primary neurons
Primary hippocampal neurons were seeded on poly-L lysine
coated coverslips in 12-well dish. After 7 DIV, the neurons were
treated with 100 ng/ml BDNF or variety of gedunin compounds
(0.5 mM) for 30 min, and then washed with PBS. Cells were fixed
with 3% formaldehyde in PBS at room temperature for 10 min.
The cells were then permeabilized and blocked by 0.4% Triton X-
100 and 2% FBS in PBS at room temperature for 15 min, washed
with PBS three times and treated with anti-MAP2 (1:200) and
anti-phospho-TrkB (816) antibodies (1:100). After staining with
FITC- or Rhodamine-conjugated secondary antibody, the cover-
slips were mounted on slides. Fluorescent images were evaluated
on an OLYMPUS IX71 fluorescence microscope.
Immunohistochemistry staining
Brain tissues were fixed in 4% paraformaldehyde overnight
followed by paraffin embedding. Sections of 6 mm were cut. For
immunohistochemical staining, brain sections were deparaffinized
in xylene and rehydrated in graded alcohols. Endogenous
peroxidase activity was blocked by 3% hydrogen peroxide for 5
minutes and all slides were boiled in 10 mM sodium citrate buffer
(pH 6.0) for 10 minutes. Phosphorylated Trk A, Trk A,
phosphorylated Trk B, and Trk B were detected using specific
antibodies and Zymed Histo-SP AEC kit (Invitrogen, USA). Slides
were then counterstained with hematoxylin.
Focal ischemia model
A total of 12 rats were used in the present study; 1 rat was
excluded because of inadequate reperfusion. Focal cerebral
ischemia was induced by occlusion of the right middle cerebral
artery as previously described [50]. Drug Administration: The
rats subjected to MCAO incurring ischemic insult ,40% of
baseline LDF were randomly assigned to receive either
deoxygedunin (n=4), 7,8-DHF (n=4), or vehicle (n=4)
treatment. Deoxygedunin and 7,8-DHF were given at the dose
of 5 mg/kg by i.p. injection 5 min prior to the onset of
reperfusion. Rats in the vehicle group underwent the same
experimental protocol, except that they received an identical
volume/weight of vehicle only. Statistical analysis: All results
were expressed as mean 6 S,E,M. Mean ischemic lesion volume
were analyzed using the Student’s t-test. The criterion for
statistical significance was set at p,0.05.
Vestibular Ganglion dissection in BDNF 2/2 pups
The cochleae of various drugs-treated pups (P1 or P2 BDNF
+/+ and 2/2 pups) were first fixed through cardioperfusion of
4% paraformaldehyde (in PBS). The cochlea was dissected out
and postfixed in 1% osmium for 1 hr at room temperature.
Samples were decalcified in 0.35 M EDTA (pH 7.5, in PBS) for
72 hrs at 4uC, followed by gradual dehydration in graded
alcohols, infiltrated, and embedded in epoxy resin with the
conventional protocols. Consecutive cochlear sections (5 mmi n
thickness) were cut with a microtome (Microm HM335E, GmbH)
along the axis of the modiolus. Sections were stained with
toluidine blue. Vestibular ganglions were identified by their
location in the auditory internal meatus with the basal cochlear
turn and the cochlear modiolus as morphological reference
landmarks.
Mouse conditioned fear studies
Following two-day habituation to testing context, wild-type
C57Bl/6J mice (N=28, male, 8–10 weeks old) were fear
conditioned in eight identical startle response systems (SR-LAB,
SDI) consisting of a nonrestrictive Plexiglas cylinder, 5.5 cm in
diameter and 13 cm long, mounted on a Plexiglas platform which
was located in a ventilated, sound-attenuated chamber. One hour
prior to fear conditioning, mice received 8-OH-Deoxygedunin
(N=14, 5 mg/kg, i.p.) or vehicle (N=14, 17%DMSO in PBS).
Mice then received 5 tone – footshock pairings, with a 30 sec
12 kHz, 85dB tones which co-terminating with footshocks
(intensity of 0.5 mA, 0.5 sec) with a 5 min intertrial interval, after
which they were returned to their homecage. 24 and 48 hrs after
training, mice were tested for freezing in rodent modular test
chambers with an inside area of 30.5 cm 624.1 cm 621.0 cm as
described previously [51,52]. Three minutes after placing the
mouse in the test chamber, 15 30 sec CS tones with an ITI of
1.5 min were delivered through a high-frequency speaker attached
to the side of each chamber. Percentage time spent freezing during
the CS presentations was calculated for each mouse using
FreezeFrame (Coulbourn Instruments, #ACT-100).
Supporting Information
Supplemental Materials S1
Found at: doi:10.1371/journal.pone.0011528.s001 (0.04 MB
DOC)
Figure S1 Chemical structures of gedunin derivatives. The first
and last chemicals (beta-dihydrogedunol and alpha-dihydrogedu-
nol) on the top row, the first one (dihydroxygedunol) in the middle
row, and the third one on the bottom row (deoxygedunin) are the
positive hits during cell-based screening and confirmed with
primary cultures.
Found at: doi:10.1371/journal.pone.0011528.s002 (0.66 MB TIF)
Figure S2 Deoxygedunin is orally active and it does not regulate
Trk receptor expression in mouse brain. (A) Two-three months old
mice (C57BL/6J) mice were orally injected with various doses of
7,8-DHF or deoxygedunin. The mice were sacrificed 2 h or 4 h
after drug administration. The brain lysates were prepared and
analyzed by immunoblotting. TrkB in mouse brain was orally
activated by these two compounds with dosage as low as 1–5 mg/
kg. (B) RT-PCR analysis of TrkA and TrkB receptors in mouse
brain after deoxygedunin treatment. (C) p-TrkB 817 antibody can
recognize phosphorylated human and mouse TrkB receptor.
Human TrkB was transfected in SH-SY5Y neuroblastoma cells.
The cells were treated with DMSO, BDNF (50 ng/ml) and
500 nM deoxygedunin for 15 min. TrkB was pulled down with
pan-Trk antibody (Santa Cruz) and analyzed by immunoblotting
with anti-p-TrkB 817. Mouse Trk receptor was immunoprecipi-
tated with anti-pan-Trk from the lysates of mouse brains. The
mice were i.p. injected with vehicle or 5 mg/kg deoxygedunin,
and sacrificed 8 h after treatment.
Found at: doi:10.1371/journal.pone.0011528.s003 (0.85 MB TIF)
Figure S3 Deoxygedunin displays potent therapeutic effects in
cell death and stroke models. (A) Deoxygedunin decreases KA-
induced apoptosis in mouse brain. The brain slides were analyzed
with TUNEL assay. Green stands for apoptotic nuclei, which were
also stained with DAPI; Kainic acid evidently initiated strong
apoptosis in hippocampal CA3 region, which was substantially
blocked by deoxygedunin (left panel). Quantitative analysis of
apoptosis in the hippocampus (right panel). (B) Deoxygedunin is
neuroprotective against stroke. TTC-stained coronal section from
representative animals given either vehicle (60% DMSO) or
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regions involving striatum and overlying cortex (left panel). Infarct
volumes after 24 h MCAO is decreased after deoxygedunin
treatment. The data are represented as mean 6 SD; * (p,0.05) =
significant difference compared to MCAO + Vehicle (right panel).
Found at: doi:10.1371/journal.pone.0011528.s004 (2.21 MB TIF)
Figure S4 Deoxygedunin is mainly concentrated in rat brain
olfactory bulb and hippocampus. Two-three months old mice
(C57BL/6J) mice were intraperitoneally injected with 30 mlo f
[3H]-deoxygedunin (26106 cpm)/DMSO/PBS solution. In 4 h,
various brain regions (A) and different organs (B) and were
analyzed by liquid scintillation counter.
Found at: doi:10.1371/journal.pone.0011528.s005 (0.62 MB TIF)
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